Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis

Clinical Infectious Diseases

Volumn 60, Issue 11, 2015, Pages 1622-1630

  Rottier, Wouter C ^a   Bamberg, Yara R P ^a   Dorigo Zetsma, J Wendelien ^b   Van Der Linden, Paul D ^b   Ammerlaan, Heidi S M ^a   Bonten, Marc J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TerGooi Hospitals   (Netherlands)

Author keywords

carbapenems; empiric antibiotic therapy; extended spectrum lactamases; inappropriate antibiotic therapy; risk factors

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; CARBAPENEM; CEPHALOSPORIN; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; BLOOD CULTURE; CLINICAL EVALUATION; DRUG USE; ENTEROBACTERIACEAE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT RISK; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEPSIS; THIRD GENERATION CEPHALOSPORIN RESISTANT ENTEROBACTERIACEAE; ADOLESCENT; AGED; DRUG EFFECTS; DRUG UTILIZATION; ENTEROBACTERIACEAE INFECTIONS; FEMALE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; NETHERLANDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CEPHALOSPORINS; DRUG UTILIZATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGIC METHODS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEPSIS; YOUNG ADULT;

EID: 84930410094     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ121     Document Type: Article

References (30)

1. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden: ECDC, 2013.
2. Pitout JDD. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 2008; 6:657-69.
3. StichtingWerkgroep Antibioticabeleid and National Institute for Public Health and the Environment. NETHMAP 2013: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. SWAB/RIVM, Nijmegen, Netherlands, 2013.
4. Paterson DL. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008; 47(suppl 1):S14-20.
5. StichtingWerkgroep Antibioticabeleid. SWAB guidelines for antibacterial therapy of adult patients with sepsis. SWAB, Amsterdam, Netherlands, 2010.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. B document M100-S22. Wayne, PA: CLSI, 2012.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. B document M100-S20. Wayne, PA: CLSI, 2010.
8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32.
9. Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamaseproducing Enterobacteriaceae bloodstream infections. Future Microbiol 2012; 7:1173-89.
10. Rodríguez-Baño J, Picón E, Gijón P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50:40-8.
11. Rodríguez-Baño J, Picón E, Gijón P, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrumbeta- lactamase-producing Escherichia coli. J Clin Microbiol 2010; 48:1726-31.
12. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 2011; 55:3485-90.
13. Leibovici L, PaulM, Nielsen AD, Tacconelli E, Andreassen S. The TREAT project: decision support and prediction using causal probabilistic networks. B J Antimicrob Agents 2007; 30(suppl 1):S93-102.
14. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
15. World Health Organization. Model prescribing information. Drugs used for bacterial infections. Geneva, Switzerland: WHO, 2001.
16. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. B Infect Dis 2011; 52:e103-20.
17. Hebert C, Ridgway J, Vekhter B, Brown EC, Weber SG, Robicsek A. B of the weighted-incidence syndromic combination antibiogram: an empiric prescribing decision aid. Infect Control Hosp Epidemiol 2012; 33:381-8.
18. Heffner AC, Horton JM, Marchick MR, Jones AE. Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. Clin Infect Dis 2010; 50:814-20.
19. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36:1006-12.
20. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851-63.
21. Frakking FNJ, Rottier WC, Dorigo-Zetsma JW, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extendedspectrum- β-lactamase-producing bacteria. Antimicrob Agents Chemother 2013; 57:3092-9.
22. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60-7.
23. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother 2013; 57:5131-3.
24. Reddy P, Malczynski M, Obias A, et al. Reply to Blot et al. Clin Infect Dis 2008; 46:482.
25. Ruppé E, Pitsch A, Tubach F, et al. Clinical predictive values of extendedspectrum beta-lactamase carriage in patients admitted to medical wards. B J Clin Microbiol Infect Dis 2012; 31:319-25.
26. Voets GM, Platteel TN, Fluit AC, et al. Population distribution of betalactamase conferring resistance to third-generation cephalosporins in human clinical Enterobacteriaceae in the Netherlands. PLoS One 2012; 7:e52102.
27. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849-58.
28. Huijbers PMC, de Kraker M, Graat EAM, et al. Prevalence of extendedspectrum β-lactamase-producing Enterobacteriaceae in humans living in municipalities with high and low broiler density. Clin Microbiol Infect 2013; 19:E256-9.
29. Valenza G, Nickel S, Pfeifer Y, et al. Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother 2014; 58:1228-30.
30. Nicolas-Chanoine M-H, Gruson C, Bialek-Davenet S, et al. 10-fold increase (2006-11) in the rate of healthy subjects with extendedspectrum β-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. J Antimicrob Chemother 2013; 68:562-8.